NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024
Joyce F. Liu, Andrew Berchuck, Floor Backes, Joshua G. Cohen, Rachel N. Grisham, Charles A. Leath, Lainie P. Martin, Daniela Matei, David S. Miller, Sharon E. Robertson, Lisa Barroilhet, Shitanshu Uppal, Andrea Wahner Hendrickson, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Angela Jain, Gottfried E. Konecny, John W. Moroney, Elena Ratner, John O. Schorge, Premal H. Thaker, Theresa L. Werner, Emese Zsíros, Kian Behbakht, Lee-may Chen, Marie DeRosa, Eric Eisenhauer, Gary S. Leiserowitz, Babak Litkouhi, Michael McHale, Sanja Percac‐Lima, Kerry J. Rodabaugh, Roberto Vargas, Frankie Jones, E Kovách, Lisa E. Hang, Swathi Ramakrishnan, Ronald D. Alvarez, Deborah K. Armstrong
Abstract
The NCCN Guidelines for Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer provide multidisciplinary diagnostic workup, staging, and treatment recommendations for this disease. These NCCN Guidelines Insights detail how the evolution of the use of PARP inhibitors as maintenance and single-agent regimens for the treatment of ovarian cancer informed panel recommendations in the guidelines.